Advanced Serious Adverse Event Reporting Regulatory Guide Part 3 – pharmaceutical regulatory consulting Advanced Serious Adverse Event Reporting Regulatory Guide Part 3 Introduction to Serious Adverse Event (SAE) Reporting Serious Adverse Events (SAEs) present critical challenges and responsibilities for clinical trial stakeholders. Recognizing the need for stringent regulatory compliance, this guide aims to provide a detailed pathway for pharmaceutical regulatory consulting in the context of SAE reporting. SAEs are defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization, prolongs existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly…